Research Article

Effect of Educational Intervention on Adverse Drug Reporting by Physicians: A Cross-Sectional Study

Manisha Bisht,1 Shruti Singh,2 and D. C. Dhasmana2

1 Department of Pharmacology, AIIMS Rishikesh, Virbhadra Road, Rishikesh, Uttarakhand 249 201, India
2 Himalayan Institute of Medical Sciences, Jolly Grant, Dehradun, Uttarakhand 248140, India

Correspondence should be addressed to Manisha Bisht; manishabisht@yahoo.co.in

Received 30 January 2014; Accepted 20 February 2014; Published 18 March 2014

Academic Editors: G. Gervasini and T. B. Vree

Copyright © 2014 Manisha Bisht et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In India, the pharmacovigilance program is still in its infancy. National Pharmacovigilance Program of India was started for facilitating the pharmacovigilance activities. The ADR reporting rate is still below satisfactory in India. This cross-sectional questionnaire based study was carried out in a tertiary care teaching hospital in Uttarakhand, which is a peripheral ADR monitoring centre to assess the level of knowledge, attitude, and the practices of pharmacovigilance among the doctors and to compare it with the group of doctors attending educational CME for improving awareness of pharmacovigilance. The most important revelation of this study was that although adequate knowledge and the right attitude about adverse drug reaction reporting were instigated in the doctors after the educational intervention, the practice was still neglectful in both groups, emphasizing the need to design the strategies to develop adverse drug reaction reporting culture.

1. Introduction

Adverse drug reactions (ADRs) are among the significant cause of morbidity and mortality worldwide [1]. ADRs not only pose a risk to the patient’s safety, but also adversely affect their quality of life and increase the healthcare cost considerably [2, 3]. ADR incidence has been reported to range from 5.9 to 22.3% of all emergency department admissions [4]. India has one of the largest drugs consuming population, with majority of people belonging to low socioeconomic group. Thus, it is the need of the hour to identify adverse drug reactions as early as possible and to prevent them if possible, for ensuring the well-being of the patient at reasonable cost. Pharmacovigilance, which relates with the detection, assessment, understanding, and prevention of ADR to medicines, is of utmost importance in this regard. In India, National Pharmacovigilance Program of India (PvPI) is responsible for conducting activities related to ADR monitoring. Spontaneous reporting of ADRs by health professionals is the corner stone of pharmacovigilance. The health professionals have major contribution in signal detection of unsuspected and unusual ADRs previously undetected during the initial evaluation of a drug [5]. The major limitation associated with spontaneous ADR reporting system is underreporting [6]. It is estimated that only 6–10% of all ADRs are reported [7]. India rates below 1% in terms of ADR reporting [8]. This clearly emphasizes that the current status of pharmacovigilance in India is far from satisfactory. Pharmacovigilance has been included in the medical undergraduate and postgraduate curriculum in many medical colleges to instigate the pharmacovigilance program. Knowledge, attitude, and the practices (KAP) analysis may provide insight into the factors associated with underreporting of ADRs. Many studies have attributed inadequate knowledge about ADRs to that of underreporting of ADRs [9–11]. Therefore, increasing awareness about pharmacovigilance should be the first step to facilitate the reporting of ADRs. This study was a humble attempt taken in that direction and it was endeavoured to assess the level of knowledge, attitude, and the practices of pharmacovigilance among the doctors and to compare it with the group of doctors attending educational CME for improving awareness of pharmacovigilance.
2. Material and Methods

This cross-sectional questionnaire based study was conducted in a tertiary care teaching hospital in Uttarakhand, which is a peripheral ADR monitoring centre (AMC) since February 2011. In December 2011, a CME was conducted by the department of pharmacology for increasing the awareness of ongoing pharmacovigilance program in the institute, which were attended by some of the faculty members and residents. During this session, physicians and resident doctors were also encouraged to report all suspected ADRs, including those that were mild or anticipated. This KAP questionnaire survey was conducted during June 2011 to August 2011 and approval from institutional ethical committee was obtained prior to administering the questionnaire survey. The survey questionnaire was administered to 125 doctors who had attended the CME and 125 doctors who had not attended the CME.

The study tool was a predesigned questionnaire adapted from previous studies with some changes to adapt local conditions [9, 12]. The final KAP questionnaire consisted of 21 questions out of which question numbers 1 to 10, 11 to 16, and 17 to 21 were designed to specifically assess the knowledge, attitude, and practice, respectively, regarding adverse reaction reporting. In order to preclude any potential bias, the disclosure of name of the responder was made optional. For ensuring the response rate, all the doctors were provided the questionnaire personally and requested to fill it on the same day and the duly filled questionnaire was collected on the same day. Suggestions on the possible ways to improve the ADR reporting were welcome.

Chi-square test was used to compare the awareness, attitude, and practice of pharmacovigilance of the doctors who had attended the educational program with that of those who had not attended educational program to evaluate the impact of the effectiveness of educational intervention among healthcare professionals; the level of statistical significance was set at $P < 0.05$.

3. Results

Out of 250 faculty members and residents that approached to participate in the study, 200 completed and returned the questionnaire, giving the response rate of 80%. The survey questionnaire was analyzed question-wise and their percentage value was calculated.

3.1. Knowledge of Physicians. Table 1 compares the knowledge of the doctors who had attended the educational CME on pharmacovigilance with that of those who had not attended it. The results revealed that the doctors who attended the educational CME have significant increase in the knowledge regarding pharmacovigilance. More doctors in the CME group (68% versus 48%; $P < 0.005$) encountered ADRs during their clinical practice and were aware of drugs banned...
due to ADR. Almost all doctors in both groups revealed that they were qualified to report adverse reactions to drugs, while pharmacists and physiotherapists were the least considered to report an ADR. Only 43% of doctors in the non-CME group were aware of the existence of PvPI as compared to 93% of doctors in the CME group and this difference was highly significant statistically. Similarly, 81% of doctors in the CME group as compared to 36% in non-CME group were aware of the AMC in the institute. Most of the doctors in both groups were not aware that adverse effects due to herbal medications also have to be reported.

3.2. Attitude of Physicians. The attitude of the doctors who had attended the educational CME on pharmacovigilance with that of those who had not attended it is compared in Table 2. The main purpose of pharmacovigilance according

| Main purpose of ADR reporting system | Doctors attending CME | Doctors not attending CME |
|--------------------------------------|------------------------|---------------------------|
| Identify safe drugs                  | 25                     | 42**                      |
| Measure the incidence of ADRs         | 33                     | 17*                       |
| Identify predisposing factors to ADRs | 26                     | 8**                      |
| Identify new ADRs                    | 17                     | 22                        |
| Comparison of ADRs within the same class | 8                     | 11                        |

| Factors encouraging ADR reporting    |                       |                           |
|--------------------------------------|------------------------|---------------------------|
| Seriousness of ADR                   | 57                     | 94*                       |
| Unusualness of ADR                   | 59                     | 53                        |
| New drug                             | 65*                    | 47**                      |
| Correct diagnosis                    | 12                     | 21                        |
| Well-recognised ADR                  | 24                     | 36                        |

| Factors discouraging ADR reporting   |                       |                           |
|--------------------------------------|------------------------|---------------------------|
| Reporting may be wrong               | 42                     | 38                        |
| Lack of time                         | 45                     | 38                        |
| Single unreported case does not affect ADR database | 57 | 33* |
| Do not know where to report          | 37                     | 57**                      |
| Do not feel the need to report ADR   | 19                     | 21                        |
| Negative impact on company marketing the drug | —               | 3                         |

| Is ADR reporting a professional obligation? |       |                   |
|---------------------------------------------|-------|-------------------|
| Yes                                         | 51    | 61                |
| No                                          | 13    | 28**              |
| Do not know                                 | 29    | 8                 |
| Perhaps                                     | 7     | 3                 |

| Which ADR should be reported?              |       |                   |
|---------------------------------------------|-------|-------------------|
| None                                        | —     | 1                 |
| All                                         | 36    | 56**              |
| All serious ADRs                            | 55    | 39**              |
| ADRs to new drugs                          | 32    | 11**              |
| Unknown ADRs to old drugs                  | 7     | 7                 |

| Opinion regarding establishment of ADR reporting centre |       |                   |
|---------------------------------------------------------|-------|-------------------|
| Should be in all hospitals                             | 68    | 58                |
| Not needed in all hospitals                            | 11    | 8                 |
| One in a city                                          | 10    | 10                |
| Depend on bed size                                     | 16    | 21                |

| ADRs reporting should be                           |       |                   |
|----------------------------------------------------|-------|-------------------|
| Compulsory                                          | 48    | 64**              |
| Voluntary                                           | 38    | 15**              |
| Rewarded                                            | 2     | 9                 |
| Hide the identity of prescriber                     | 6     | 6                 |
| Hide the identity of reporter                       | 6     | 6                 |

*P < 0.005; **P < 0.0001; ***P < 0.05; ****P < 0.001.
Table 3: Attitude of the physicians of both groups regarding pharmacovigilance.

| Sources used to gather information about ADRs          | Doctors attending CME | Doctors not attending CME |
|------------------------------------------------------|-----------------------|---------------------------|
| Textbooks                                            | 38                    | 40                        |
| Journals                                             | 69                    | 42                        |
| Medical representatives                              | 7                     | 17                        |
| Internet                                             | 63                    | 49                        |
| Seminar/conferences                                  | 65                    | 22                        |
| Drug promotional literature                           | 9                     | 26                        |

| ADRs reported till now                               |                       |                           |
|------------------------------------------------------|-----------------------|---------------------------|
| None                                                 | 77                    | 68                        |
| 1–5                                                  | 15                    | 25                        |
| 6–10                                                 | 1                     | 7                         |
| 15–20                                                | 4                     | —                         |
| Free access to ADR reporting form                    | 63                    | 19                        |
| Information was clear on the form                    | 58                    | 14                        |
| Need for training on filling of ADR reporting form   | 90                    | 82                        |

| Method preferred for reporting ADR information        |                       |                           |
|------------------------------------------------------|-----------------------|---------------------------|
| Direct contact                                       | 40                    | 32                        |
| Telephone                                            | 26                    | 25                        |
| Email                                                | 44                    | 54                        |
| Self                                                 | 15                    | 7                         |
| Other                                                | 17                    | 4                         |

*P < 0.005; **P < 0.0001; ***P < 0.05; ****P < 0.001.

to the doctors who had attended the CME was to identify predisposing factors to ADRs followed by the identification of safe drugs. The doctors in the other group (not attended the CME) recognised the identification of safe drugs and new ADRs as the main purpose of pharmacovigilance. In the CME group, most respondents were encouraged to report ADRs if the reaction was to a new product (65% versus 47%; *P < 0.05), whereas in non-CME group the seriousness of the ADRs was the most important factor (94% versus 57%; *P < 0.0001). Figure 1 represents the major reasons for not reporting ADR by physicians. In the CME group, the notion that reporting of only one ADR makes no significant contribution to the ADR database (57% versus 33%; *P < 0.0001) was the most important reason which discouraged the physician from ADR reporting. In contrast, unawareness of the reporting centre (57% versus 37%; *P < 0.05) was the most important discouraging factor in ADR reporting among doctors in non-CME group. A good number of doctors in both groups (51%, 61%) were of the opinion that ADR reporting is a professional obligation for them while nearly one-third of patients in non-CME group did not consider ADR reporting as a professional obligation (28% versus 13%; *P < 0.05). In CME group, majority of doctors opined that all serious ADRs should be reported (55% versus 39%; *P < 0.05), whereas most doctors in non-CME group felt that all ADRs should be reported (56% versus 36%; *P < 0.05). Majority of doctors in both groups (58%, 68%) opined that ADR reporting centre should be established in all the hospitals. Most of the doctors in both groups especially non-CME group felt that ADR reporting should be compulsory (48% versus 64%; *P < 0.05).

3.3. Practice of Doctors. The comparison of practice of the doctors who had attended the educational CME on pharmacovigilance with that of those who had not attended it is given in Table 3. Majority of doctors in the CME group conveyed that they updated their knowledge regarding ADRs of new drugs from scientific journals (69%), seminars (65%), and internet (63%), whereas doctors in non-CME group preferred sources like internet (49%), scientific journals (42%), and textbooks (40%) for updating their knowledge regarding ADRs of new drugs. Doctors in the CME group acknowledged more free access to ADR reporting form as compared to doctors in non-CME group (63% versus 19%; *P < 0.0001). Interestingly, majority of doctors in both groups (77% versus 68%) did not report any ADR to date (Figure 2). Majority of doctors in the CME group admitted that the information on the ADR reporting form was clear as compared to the doctors in non-CME group (58% versus 14%; *P < 0.0001). Most of the doctors in both groups felt the need for training on filling of ADR reporting form. Regarding the mode of reporting ADRs, the doctors in both groups preferred e-mail followed by direct contact. Both groups of doctors (CME group—56%; non-CME group—51%) mentioned that attending conferences and continuing medical education (CME) and other similar activities would facilitate the significance of PhV and majority of them emphasised the need to conduct such activities periodically.
Reporting may be wrong
Lack of time
Single unreported case
does not affect ADR database
Do not feel the need to report ADR
Negative impact on company marketing the drug

Figure 1: Graph showing the factors discouraging the ADR reporting among the physicians of both groups.

Figure 2: ADR observed and reported by physician of both groups.

4. Discussion
In India, the pharmacovigilance related activity was started initially in 1986 [13]. After initial futile attempts, Ministry of Health and Family Welfare, Government of India, relaunched this program as Pharmacovigilance Program of India (PvPI) in July 2010 [14]. Since then, continuous efforts are being made to strengthen the PvPI by including more and more MCI recognised medical colleges in this program. This study was conducted in a tertiary care teaching hospital after the pharmacovigilance program was started. It was a cross-sectional questionnaire based study, comparing the level of knowledge, attitude, and practice of pharmacovigilance between doctors who were educated on the subject of pharmacovigilance through a CME based educational program with that of other doctors who were not.

This study highlighted that significantly less number of doctors, who had not attended educational CME on pharmacovigilance, had the adequate knowledge of pharmacovigilance. Many studies conducted in India have also reported poor knowledge of doctors regarding pharmacovigilance [15, 16]. The doctors who had attended the CME on pharmacovigilance had increased awareness regarding the pharmacovigilance program and ADR monitoring. Similarly, previous studies have also confirmed that educational intervention leads to increased awareness regarding pharmacovigilance [12, 17]. Thus, continuous efforts are required for increasing the awareness of pharmacovigilance through the provision of appropriate education and training programmes at regular intervals for ADR reporting. Majority of doctors in both groups had encountered ADRs during their clinical practice. This was an encouraging finding as recognition of ADR is the first step of pharmacovigilance. However, other studies have reported higher number of doctors encountering ADRs during their clinical practice [16, 18]. This reflects that there is further need to enhance the knowledge of the doctors in the institute regarding ADR.

The most common discouraging factor for ADR reporting in doctors not educated on pharmacovigilance was...
the lack of knowledge on where to report indicating ignorance. This factor is adequately taken care of by increasing the awareness about existing pharmacovigilance centre, as reflected in our results where more than 60% of doctors in CME group were aware of as to where to report. On the other hand, most common notion of doctors in the CME group was that single unreported case does not affect ADR database reflecting indifferent attitude towards ADR reporting. Other studies have also reported similar attitudes regarding ADR monitoring [9]. The indifference in attitude regarding ADR reporting should be specifically addressed by emphasising the need to report all ADRs, as it significantly influences the ADR reporting among the doctors. The doctors in non-CME group were more willing to report to serious and unusual ADR but only one-third of doctors felt the need to report all ADRs. Whereas more than half of the doctors in CME group felt the need to report all ADR and preferred to report ADR with new drug or unusual side effect of old drugs. This reflects that educational intervention can emphasise the need to report all ADRs and doctors may be willing to report all ADRs if adequate knowledge is imparted to them. Moreover, doctors in both groups had a positive attitude towards ADR monitoring. Most of them opined that pharmacovigilance centre should be established in all the hospitals and ADR reporting should be compulsory. This indicates that doctors are keen to learn and practice pharmacovigilance if proper knowledge and training about ADRs reporting are imparted to them.

In this study, it was observed that more doctors in the CME group as compared to non-CME encountered ADRs during their clinical practice (68% versus 48%) but the number of doctors who had ever reported ADR was similarly inadequate in both groups (23% versus 21%). Similar trend in terms of ADR encountered and ADR reporting was observed in other studies also. Various studies have reported that though majority of doctors felt the need of ADR reporting and they frequently encounter ADRs during their clinical practice but most of them have never reported any ADR [9, 19, 20]. This reflects that even though awareness of ADR reporting can be increased by initial educational intervention, more effort is required to influence the practice of ADR reporting. In some countries like UK, France, The Netherlands, and Sweden, the ADR reporting rates are much higher ranging from 40 to 70% [9, 20–24]. The main reason for this may be that in these countries ADR monitoring system is well established and ADR reporting is mandatory.

The most important revelation of this study was that although adequate knowledge and the right attitude about ADR reporting were instigated in the doctors after the educational intervention, the practice was still neglectful in both groups. Though, initially, there was an increase in the number of ADR reports after the educational intervention, there was again a decline in the numbers after some time (Figure 3). Another study has also reported similar findings where an educational intervention improved physician awareness of ADRs and the same was incorporated into their everyday clinical practice [25]. However, similar to our study, the effects of the educational intervention were temporary.

Fostering a positive ADR reporting culture amongst the clinicians is indeed a difficult task. The awareness about pharmacovigilance should commence from the beginning and it should be incorporated in the medical teaching and training curriculum. Besides this, continuous education programmes should be carried out to emphasize the importance of ADR reporting and regular communication with clinician’s should be carried out to explain the reporting procedures and thereby inculcate the habit of ADR reporting. As expected, lack of time was accounted as the second most discouraging factor for ADR reporting in both groups. Therefore, the most important factor to reinforce the pharmacovigilance is to provide an easy and quick method of reporting. Apart from this, the study participants also suggested that
the acknowledgment of the receipt of the report and the outcome of the reporting helps in motivating them to continue the pharmacovigilance activities.

Previously, many studies have been carried out in India as well as abroad to assess the KAP of doctors regarding ADR monitoring [9, 11, 12, 17]. This study was a step further where we had tried to compare the impact of educational intervention on the KAP of pharmacovigilance in doctors. Most significant conclusion of our study was that even though educational intervention improves the knowledge regarding pharmacovigilance, its impact on practice is relatively transient. This study opens new avenues for further research for the assessment of the strategies that are helpful in improving the practice of pharmacovigilance.

5. Conclusion

Pharmacovigilance can survive only on the spontaneous reporting by the healthcare professionals, which in turn depends on their good knowledge about PhV as well as their willingness to report. Our study concludes that creating awareness among the healthcare professionals and promoting ADR reporting are the need of the hour. Organising regular workshops and continuous medical education will improve the awareness of healthcare professional regarding PV and other strategies have to be developed for facilitating the ADR reporting culture in our country.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] W. Wu and N. Pantaleo, “Evaluation of outpatient adverse drug reactions leading to hospitalization,” *American Journal of Health-System Pharmacy*, vol. 60, no. 3, pp. 253–259, 2003.
[2] M. Pirmohamed, S. James, S. Meakin et al., “Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients,” *British Medical Journal*, vol. 329, no. 7456, pp. 15–19, 2004.
[3] R. Rodriguez-Monguio, M. J. Otero, and J. Rovira, “Assessing the economic impact of adverse drug effects,” *Pharmacoeconomics*, vol. 21, no. 9, pp. 623–650, 2003.
[4] K. Nelson and R. Talbert, “Drug-related hospital admissions,” *Pharmacotherapy*, vol. 16, no. 4, pp. 701–707, 1996.
[5] D. Wysowski and L. Swartz, “Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions,” *Archives of Internal Medicine*, vol. 165, no. 12, pp. 1363–1369, 2005.
[6] E. Lopez-Gonzalez, M. T. Herdeiro, and A. Figueiras, “Determinants of under-reporting of adverse drug reactions: a systematic review,” *Drug Safety*, vol. 32, no. 1, pp. 19–31, 2009.
[7] C. Smith, P. Bennett, H. Pearce et al., “Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines,” *British Journal of Clinical Pharmacology*, vol. 42, no. 4, pp. 423–429, 1996.
[8] S. Prakash, “Pharmacovigilance in India,” *Indian Journal of Pharmacology*, vol. 39, no. 3, p. 123, 2007.
[9] K. A. Oshikoya and J. O. Awobusuyi, “Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria,” *BMC Clinical Pharmacology*, vol. 9, p. 14, 2009.
[10] H. S. Rehan, K. Vasudev, and C. D. Tripathi, “Adverse drug reaction monitoring: knowledge, attitude and practices of medical students and prescribers,” *The National Medical Journal of India*, vol. 15, no. 1, pp. 24–26, 2002.
[11] J. O. Fadare, O. O. Enwere, A. O. Afolabi, B. A. Z. Chedi, and A. Musa, “Knowledge, attitude and practice of adverse drug reaction reporting among healthcare workers in a tertiary centre in Northern Nigeria,” *Tropical Journal of Pharmaceutical Research*, vol. 10, no. 3, pp. 235–242, 2011.
[12] R. Radhakrishnan, V. Sudha, and M. V. Danturulu, “An educational intervention to assess knowledge attitude practice of pharmacovigilance among Health care professionals in an Indian tertiary care teaching hospital,” *International Journal of PharmTech Research*, vol. 3, no. 2, pp. 678–692, 2011.
[13] R. D. Kulkarni, “Reporting systems for rare side effects of non-narcotic analgesics in India. Problems and opportunities,” *Medical Toxicology and Adverse Drug Experience*, vol. 1, no. 1, pp. 110–113, 1986.
[14] Y. K. Gupta, “Ensuring patient safety-launching the new pharmacovigilance programme of India,” *Pharma Times*, vol. 42, no. 8, pp. 21–26, 2010.
[15] S. Khan, C. Goyal, N. Chandel, and M. Rafi, “Knowledge, attitudes and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: an observational study,” *Journal of Natural Science, Biology and Medicine*, vol. 4, no. 1, pp. 191–196, 2013.
[16] C. Desai, G. Iyer, J. Panchal, S. Shah, and R. Dikshit, “An evaluation of knowledge, attitude and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital,” *Perspectives in Clinical Research*, vol. 2, no. 4, pp. 129–136, 2011.
[17] Q. Li, S. Zhang, H. Chen et al., “Awareness and attitudes of healthcare professionals in Wuhan, China to the reporting of adverse drug reactions,” *Chinese Medical Journal*, vol. 117, no. 6, pp. 856–861, 2004.
[18] K. Santosh, T. Pramote, G. Sarun, and E. Ralph, “Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal,” *BMC Pharmacology and Toxicology*, vol. 14, p. 16, 2013.
[19] S. Chatterjee, N. Lyle, and S. Ghosh, “A survey of the knowledge, attitude and practice of adverse drug reaction reporting by clinicians in eastern India,” *Drug Safety*, vol. 29, no. 7, pp. 641–642, 2006.
[20] E. Ekman and M. Bäckström, “Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden,” *European Journal of Clinical Pharmacology*, vol. 65, no. 1, pp. 43–46, 2009.
[21] K. J. Belton, S. C. Lewis, S. Payne, M. D. Rawlins, and S. M. Wood, “Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom,” *British Journal of Clinical Pharmacology*, vol. 39, no. 3, pp. 223–226, 1995.
[22] K. Belton, “Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group,” *European Journal of Clinical Pharmacology*, vol. 52, no. 6, pp. 423–427, 1997.
[23] E. Ekman and M. Bäckström, “Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden,” *European Journal of Clinical Pharmacology*, vol. 65, no. 1, pp. 43–46, 2009.
[24] I. A. Eland, K. J. Belton, A. C. Van Grootheest, A. P. Meiners, M. D. Rawlins, and B. H. C. Stricker, “Attitudinal survey of voluntary reporting of adverse drug reactions,” *British Journal of Clinical Pharmacology*, vol. 48, no. 4, pp. 623–627, 1999.

[25] M. Tabali, E. Jeschke, A. Bockelbrink et al., “Educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine,” *BMC Public Health*, vol. 9, p. 274, 2009.